XML 31 R20.htm IDEA: XBRL DOCUMENT v3.20.2
Business Segments and Geographic Information
 9 Months Ended
Jun. 27, 2020
Segment Reporting [Abstract]  
Business Segments and Geographic Information Business Segments and Geographic InformationDuring the first fiscal quarter of 2020 and fiscal 2019, the Company had five reportable segments: Diagnostics, Breast Health, GYN Surgical, Medical Aesthetics and Skeletal Health. The Company completed the sale of its Medical Aesthetics business on December 30, 2019, but will continue to have operating expenses primarily related to indemnifying CD&R for legal and tax matters that existed as of the date of disposition. The Company measures and evaluates its reportable segments based on segment revenues and operating income adjusted to exclude the effect of non-cash charges, such as intangible asset amortization expense, intangible asset and goodwill impairment charges, acquisition related fair value adjustments and integration expenses, restructuring, divestiture and facility consolidation charges and other one-time or unusual items.
Identifiable assets for the reportable segments consist of inventories, intangible assets, goodwill, and property, plant and equipment. The Company fully allocates depreciation expense to its reportable segments. The Company has presented all other identifiable assets as corporate assets. There were no inter-segment revenues during the three and nine months ended June 27, 2020 and June 29, 2019. Segment information is as follows:
 Three Months EndedNine Months Ended
 June 27,
2020		June 29,
2019		June 27,
2020		June 29,
2019
Total revenues:
Diagnostics$532.2  $305.4  $1,163.2  $898.6  
Breast Health224.0  325.4  862.8  971.6  
GYN Surgical51.5  112.2  275.9  322.8  
Medical Aesthetics—  85.0  65.3  238.6  
Skeletal Health15.2  24.4  62.3  69.8  
$822.9  $852.4  $2,429.5  $2,501.4  
Income (loss) from operations:
Diagnostics$233.9  $45.7  $340.7  $120.1  
Breast Health(11.1) 97.5  158.6  294.3  
GYN Surgical(23.4) 22.5  32.0  70.0  
Medical Aesthetics(1.0) (18.6) (54.3) (517.6) 
Skeletal Health(7.4) (1.8) (4.8) (4.1) 
$191.0  $145.3  $472.2  $(37.3) 
Depreciation and amortization:
Diagnostics$59.4  $61.6  $177.8  $184.9  
Breast Health13.0  9.3  36.2  27.5  
GYN Surgical21.0  21.9  63.1  65.8  
Medical Aesthetics—  20.4  4.1  71.0  
Skeletal Health0.2  0.1  0.5  0.5  
$93.6  $113.3  $281.7  $349.7  
Capital expenditures:
Diagnostics$28.4  $14.2  $63.7  $44.7  
Breast Health3.0  3.0  17.5  9.7  
GYN Surgical2.4  4.3  12.9  10.9  
Medical Aesthetics—  1.2  1.4  5.7  
Skeletal Health0.1  0.4  0.3  1.0  
Corporate1.1  2.7  2.2  5.7  
$35.0  $25.8  $98.0  $77.7  
 
June 27,
2020		September 28,
2019
Identifiable assets:
Diagnostics$2,169.0  $2,276.6  
Breast Health1,225.8  1,127.8  
GYN Surgical1,271.6  1,328.6  
Medical Aesthetics—  159.3  
Skeletal Health32.4  27.3  
Corporate2,104.3  1,522.5  
$6,803.1  $6,442.1  
The Company had no customers that represented greater than 10% of consolidated revenues during the three and nine months ended June 27, 2020 and June 29, 2019.
The Company operates in the major geographic areas noted in the below chart. Revenue data is based upon customer location. Other than the United States, no single country accounted for more than 10% of consolidated revenues. The Company’s sales in Europe are predominantly derived from France, Germany and the United Kingdom. The Company’s sales in Asia-Pacific are predominantly derived from China, Australia and Japan. The “Rest of World” designation includes Canada, Latin America and the Middle East.
Revenues by geography as a percentage of total revenues were as follows:
 
 Three Months EndedNine Months Ended
 June 27,
2020		June 29,
2019		June 27,
2020		June 29,
2019
United States80.3 %75.4 %76.9 %75.1 %
Europe12.4 %11.3 %13.3 %12.0 %
Asia-Pacific5.3 %8.9 %6.4 %8.4 %
Rest of World2.0 %4.4 %3.4 %4.5 %
100.0 %100.0 %100.0 %100.0 %